Tags

Type your tag names separated by a space and hit enter

Reduced hypoglycemic episodes and improved glycemic control in children with type 1 diabetes using insulin glargine and neutral protamine Hagedorn insulin.
J Pediatr. 2003 Dec; 143(6):737-40.JPed

Abstract

OBJECTIVE

The purpose of this study was to evaluate the use of a new long-acting basal insulin, insulin glargine (IG), in children with type 1 diabetes. Study design Data from 114 subjects, age 2 to 18 years (mean, 12.2 years; 54 boys, 60 girls), were collected for 9 months before and 9 months after IG treatment. During IG therapy, all subjects received morning neutral protamine Hagedorn insulin (given with insulin lispro; Humalog) to provide daytime insulin coverage. The numbers of nonsevere and severe hypoglycemic events, hemoglobin A1c values, body weight, and daily insulin dose were recorded at each clinic visit.

RESULTS

The mean (+/-1 SEM) frequency of nonsevere hypoglycemic events per week decreased from 2.0+/-0.1 to 1.3+/-0.1 (P<.001). Severe hypoglycemic episodes were reduced from a total of 22 in the 9 months before IG to nine in the 9 months after IG. Severe nocturnal events were similarly reduced from 14 to four episodes. The mean (+/-1 SEM) hemoglobin A1c levels were 9.6+/-0.1% (baseline), 9.4+/-0.1% at 3 months (P=.18), 9.3+/-0.1% at 6 months (P=.03), and 9.3+/-0.1% at 9 months (P=.01).

CONCLUSION

Insulin glargine therapy can reduce hypoglycemic episodes in children and adolescents with suboptimal glucose control without jeopardizing glycemic control.

Authors+Show Affiliations

Chase HP
Department of Pediatrics, Barbara Davis Center for Childhood Diabetes, University of Colorado Health Science Center, Denver, Colorado, USA. peter.chase@uchsc.edu
Dixon B
No affiliation info available
Pearson J
No affiliation info available
Fiallo-Scharer R
No affiliation info available
Walravens P
No affiliation info available
Klingensmith G
No affiliation info available
Rewers M
No affiliation info available
Garg SK
No affiliation info available

MeSH

AdolescentChildChild, PreschoolDiabetes Mellitus, Type 1Drug Administration ScheduleFemaleGlycated HemoglobinHumansHypoglycemiaHypoglycemic AgentsInsulinInsulin GlargineInsulin LisproInsulin, IsophaneInsulin, Long-ActingMale

Pub Type(s)

Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

14657818

Citation

Chase, H Peter, et al. "Reduced Hypoglycemic Episodes and Improved Glycemic Control in Children With Type 1 Diabetes Using Insulin Glargine and Neutral Protamine Hagedorn Insulin." The Journal of Pediatrics, vol. 143, no. 6, 2003, pp. 737-40.
Chase HP, Dixon B, Pearson J, et al. Reduced hypoglycemic episodes and improved glycemic control in children with type 1 diabetes using insulin glargine and neutral protamine Hagedorn insulin. J Pediatr. 2003;143(6):737-40.
Chase, H. P., Dixon, B., Pearson, J., Fiallo-Scharer, R., Walravens, P., Klingensmith, G., Rewers, M., & Garg, S. K. (2003). Reduced hypoglycemic episodes and improved glycemic control in children with type 1 diabetes using insulin glargine and neutral protamine Hagedorn insulin. The Journal of Pediatrics, 143(6), 737-40.
Chase HP, et al. Reduced Hypoglycemic Episodes and Improved Glycemic Control in Children With Type 1 Diabetes Using Insulin Glargine and Neutral Protamine Hagedorn Insulin. J Pediatr. 2003;143(6):737-40. PubMed PMID: 14657818.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Reduced hypoglycemic episodes and improved glycemic control in children with type 1 diabetes using insulin glargine and neutral protamine Hagedorn insulin. AU - Chase,H Peter, AU - Dixon,Brenner, AU - Pearson,Jerusha, AU - Fiallo-Scharer,Rosanna, AU - Walravens,Philippe, AU - Klingensmith,Georgeanna, AU - Rewers,Marian, AU - Garg,Satish K, PY - 2003/12/6/pubmed PY - 2004/1/9/medline PY - 2003/12/6/entrez SP - 737 EP - 40 JF - The Journal of pediatrics JO - J Pediatr VL - 143 IS - 6 N2 - OBJECTIVE: The purpose of this study was to evaluate the use of a new long-acting basal insulin, insulin glargine (IG), in children with type 1 diabetes. Study design Data from 114 subjects, age 2 to 18 years (mean, 12.2 years; 54 boys, 60 girls), were collected for 9 months before and 9 months after IG treatment. During IG therapy, all subjects received morning neutral protamine Hagedorn insulin (given with insulin lispro; Humalog) to provide daytime insulin coverage. The numbers of nonsevere and severe hypoglycemic events, hemoglobin A1c values, body weight, and daily insulin dose were recorded at each clinic visit. RESULTS: The mean (+/-1 SEM) frequency of nonsevere hypoglycemic events per week decreased from 2.0+/-0.1 to 1.3+/-0.1 (P<.001). Severe hypoglycemic episodes were reduced from a total of 22 in the 9 months before IG to nine in the 9 months after IG. Severe nocturnal events were similarly reduced from 14 to four episodes. The mean (+/-1 SEM) hemoglobin A1c levels were 9.6+/-0.1% (baseline), 9.4+/-0.1% at 3 months (P=.18), 9.3+/-0.1% at 6 months (P=.03), and 9.3+/-0.1% at 9 months (P=.01). CONCLUSION: Insulin glargine therapy can reduce hypoglycemic episodes in children and adolescents with suboptimal glucose control without jeopardizing glycemic control. SN - 0022-3476 UR - https://www.unboundmedicine.com/medline/citation/14657818/Reduced_hypoglycemic_episodes_and_improved_glycemic_control_in_children_with_type_1_diabetes_using_insulin_glargine_and_neutral_protamine_Hagedorn_insulin_ DB - PRIME DP - Unbound Medicine ER -
Grapherence [↓17]

Related Citations

More